John Hohneker
Direktor/Vorstandsmitglied bei CARISMA THERAPEUTICS, INC.
Vermögen: - $ am 30.04.2024
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| James Dentzer | M | 57 | 8 Jahre | |
| Hans Jörg Reinhardt | M | 68 | 40 Jahre | |
| Diantha Duvall | F | 52 | 2 Jahre | |
| Volker Herrmann | M | - |
Sonata Therapeutics, Inc.
 Sonata Therapeutics, Inc. BiotechnologyHealth Technology Sonata Therapeutics, Inc. is a pioneering private company based in Cambridge, MA that designs single therapeutics to reprogram diseased cells and create curative microenvironments. The company's machine learning-based platform identifies novel insights, targets, and therapeutics across a wide range of disease areas, with a growing pipeline of small molecule drugs and genetic therapeutics. In oncology, Sonata's transformative therapies reprogram cancer cells to release curative signals that reverse immune cell suppression and blockade, empowering the immune system to holistically eradicate tumors and drive cure. Sonata Therapeutics is creating a new class of network medicines™ designed to modulate all the key cell types in a disease microenvironment required to drive disease resolution. The company is also exploring additional therapeutic areas such as fibrosis and tissue regeneration where multicellular networks play a key role. The company has subsidiaries in the United States. The company was founded in 2022 by flagship pioneering, and the CEO is Volker Herrmann. | - |
| Robert Martell | M | 61 | 13 Jahre | |
| Steven Kelly | M | 59 | 6 Jahre | |
| Martyn Greenacre | M | 82 | 24 Jahre | |
| Anil Singhal | M | 72 |
Trishula Therapeutics, Inc.
 Trishula Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trishula Therapeutics, Inc. is a company solely dedicated to developing TTX-030, a first-in-class anti-CD39 antibody aimed at improving outcomes for people with cancer. Trishula Therapeutics is based in South San Francisco, CA. The company's leadership, board of directors, scientific advisory board, investors, and partners are all committed to this goal. Anil Singhal has been the CEO of the company since 2021. | 3 Jahre |
| Stuart Lutzker | M | 63 | 3 Jahre | |
| Richard Morris | M | 51 | 3 Jahre | |
| Zheng Bin Yao | M | 58 | 3 Jahre | |
| Bill Winters | M | 62 | 11 Jahre | |
| Mark W. Noel | M | 65 | 23 Jahre | |
| Nancy Andrews | M | 65 | 9 Jahre | |
| Samir Shah | M | 63 | 20 Jahre | |
| Michael Torok | M | 45 | 1 Jahre | |
| Karah Parschauer | F | 46 | 7 Jahre | |
| Vasant Narasimhan | M | 48 | 19 Jahre | |
| Winston Kung | M | 48 | - | |
| Michael Klichinsky | M | 34 | 8 Jahre | |
| Jonathan Zung | M | 59 | 3 Jahre | |
| Scott Clarke | M | - |
Trishula Therapeutics, Inc.
Trishula Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trishula Therapeutics, Inc. is a company solely dedicated to developing TTX-030, a first-in-class anti-CD39 antibody aimed at improving outcomes for people with cancer. Trishula Therapeutics is based in South San Francisco, CA. The company's leadership, board of directors, scientific advisory board, investors, and partners are all committed to this goal. Anil Singhal has been the CEO of the company since 2021. | 4 Jahre |
| Christian Nolet | M | 67 | 1 Jahre | |
| Jim Kastenmayer | M | 52 | 1 Jahre | |
| Eric Siegel | M | 60 | 1 Jahre | |
| Charles Sawyers | M | 65 | 11 Jahre | |
| Anne Borgman | M | 56 | 2 Jahre | |
| Bahija Jallal | M | 62 | 2 Jahre | |
| Sanford Zweifach | M | 68 | 3 Jahre | |
| Briggs Morrison | M | 65 | 4 Jahre | |
| Kenneth Kaitin | M | 71 | 21 Jahre | |
| Björn Ingemar Odlander | M | 66 | 2 Jahre | |
| Carl Gordon | M | 59 | 2 Jahre | |
| Marc Rubin | M | 69 | 14 Jahre | |
| James Healy | M | 59 | 1 Jahre | |
| Regina Hodits | M | 53 | 6 Jahre | |
| Nancy Soohoo | F | - | 21 Jahre | |
| Mark D. Plinio | M | 57 | 3 Jahre | |
| Dora Ferrari | F | - | 3 Jahre | |
| Kimberly Steinmann | M | - | 2 Jahre | |
| Anthony Melendez | M | - |
Trishula Therapeutics, Inc.
Trishula Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trishula Therapeutics, Inc. is a company solely dedicated to developing TTX-030, a first-in-class anti-CD39 antibody aimed at improving outcomes for people with cancer. Trishula Therapeutics is based in South San Francisco, CA. The company's leadership, board of directors, scientific advisory board, investors, and partners are all committed to this goal. Anil Singhal has been the CEO of the company since 2021. | 3 Jahre |
| Rachel Blasbalg | F | - | 20 Jahre | |
| Maria Petrini | F | - | 1 Jahre | |
| Terry Shields | F | - | 1 Jahre | |
| Reinhard von Roemeling | M | - | 5 Jahre | |
| Scott Brun | M | 56 |
Trishula Therapeutics, Inc.
Trishula Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trishula Therapeutics, Inc. is a company solely dedicated to developing TTX-030, a first-in-class anti-CD39 antibody aimed at improving outcomes for people with cancer. Trishula Therapeutics is based in South San Francisco, CA. The company's leadership, board of directors, scientific advisory board, investors, and partners are all committed to this goal. Anil Singhal has been the CEO of the company since 2021. | - |
| Thomas Kassberg | M | 63 | 7 Jahre | |
| Douglas Cole | M | 63 |
Sonata Therapeutics, Inc.
Sonata Therapeutics, Inc. BiotechnologyHealth Technology Sonata Therapeutics, Inc. is a pioneering private company based in Cambridge, MA that designs single therapeutics to reprogram diseased cells and create curative microenvironments. The company's machine learning-based platform identifies novel insights, targets, and therapeutics across a wide range of disease areas, with a growing pipeline of small molecule drugs and genetic therapeutics. In oncology, Sonata's transformative therapies reprogram cancer cells to release curative signals that reverse immune cell suppression and blockade, empowering the immune system to holistically eradicate tumors and drive cure. Sonata Therapeutics is creating a new class of network medicines™ designed to modulate all the key cell types in a disease microenvironment required to drive disease resolution. The company is also exploring additional therapeutic areas such as fibrosis and tissue regeneration where multicellular networks play a key role. The company has subsidiaries in the United States. The company was founded in 2022 by flagship pioneering, and the CEO is Volker Herrmann. | - |
| David Scadden | M | 71 |
Sonata Therapeutics, Inc.
Sonata Therapeutics, Inc. BiotechnologyHealth Technology Sonata Therapeutics, Inc. is a pioneering private company based in Cambridge, MA that designs single therapeutics to reprogram diseased cells and create curative microenvironments. The company's machine learning-based platform identifies novel insights, targets, and therapeutics across a wide range of disease areas, with a growing pipeline of small molecule drugs and genetic therapeutics. In oncology, Sonata's transformative therapies reprogram cancer cells to release curative signals that reverse immune cell suppression and blockade, empowering the immune system to holistically eradicate tumors and drive cure. Sonata Therapeutics is creating a new class of network medicines™ designed to modulate all the key cell types in a disease microenvironment required to drive disease resolution. The company is also exploring additional therapeutic areas such as fibrosis and tissue regeneration where multicellular networks play a key role. The company has subsidiaries in the United States. The company was founded in 2022 by flagship pioneering, and the CEO is Volker Herrmann. | - |
| Kurt von Emster | M | 56 |
Trishula Therapeutics, Inc.
Trishula Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trishula Therapeutics, Inc. is a company solely dedicated to developing TTX-030, a first-in-class anti-CD39 antibody aimed at improving outcomes for people with cancer. Trishula Therapeutics is based in South San Francisco, CA. The company's leadership, board of directors, scientific advisory board, investors, and partners are all committed to this goal. Anil Singhal has been the CEO of the company since 2021. | 4 Jahre |
| Patricia Allen | F | 62 |
Anokion SA
 Anokion SA Medical/Nursing ServicesHealth Services Anokion SA provides technology for retraining white blood cells to induce therapeutic immune tolerance. The firm?s approach to antigen-specific immune tolerance can be translated to virtually any protein in numerous clinical indications. The company was founded by Jerffery Hubbell, Melody Swartz, Stephan Kontos, Oscar Buset, Kristen M. Lorentz and David A. Lowin and is headquartered in Ecublens, Switzerland. | 4 Jahre |
| Shalini Sharp | F | 49 | 7 Jahre | |
| Robin LaChapelle | F | 51 | 1 Jahre | |
| Charlotte Pamer-Wieser | M | - | 13 Jahre | |
| Leonard Dove | M | 51 | 2 Jahre | |
| Daniel Cushing | M | - | 7 Jahre | |
| Laura Brass | M | - |
Anokion SA
Anokion SA Medical/Nursing ServicesHealth Services Anokion SA provides technology for retraining white blood cells to induce therapeutic immune tolerance. The firm?s approach to antigen-specific immune tolerance can be translated to virtually any protein in numerous clinical indications. The company was founded by Jerffery Hubbell, Melody Swartz, Stephan Kontos, Oscar Buset, Kristen M. Lorentz and David A. Lowin and is headquartered in Ecublens, Switzerland. | 5 Jahre |
| Tom Wilton | M | - | 5 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Timothy Morris | M | 61 | 6 Jahre | |
| William Steinkrauss | M | 39 | 6 Jahre | |
| Ronen Tamir | M | 57 | - | |
| David Epstein | M | 62 | 6 Jahre | |
| Annalisa Jenkins | M | 58 | 3 Jahre | |
| Wendelin Wiedeking | M | 72 | 11 Jahre | |
| Ann Thorell | F | 56 | 1 Jahre | |
| Jean Franchi | F | 57 | 2 Jahre | |
| Rolf M. Zinkernagel | M | 80 | 15 Jahre | |
| Ulrich Lehner | M | 78 | 13 Jahre | |
| Joseph Jimenez | M | 64 | 11 Jahre | |
| Lord Darzi | M | 63 | 5 Jahre | |
| Christine Bellon | M | 59 |
FORMA Therapeutics, Inc.
 FORMA Therapeutics, Inc. BiotechnologyHealth Technology FORMA Therapeutics, Inc. discovers and develops medicines for cancer and other genetically driven diseases. Its drug discovery engine deploys screening and structure-based approaches across broad families of targets involved in tumor metabolism, epigenetics, protein homeostasis, and protein-protein interactions. The company was founded by Steven Tregay, Nikolai Kley, Stuart L. Schreiber, Todd R. Golub, Michael Foley and Alexis Borisy in 2008 and is headquartered in Watertown, MA. | 2 Jahre |
| Verena A. Briner | M | 72 | 3 Jahre | |
| Peter Maag | M | 56 | 5 Jahre | |
| Luca Scavo | M | 57 | 1 Jahre | |
| Eric Zhang | M | 43 | 5 Jahre | |
| Karoline Shair | M | - |
FORMA Therapeutics, Inc.
FORMA Therapeutics, Inc. BiotechnologyHealth Technology FORMA Therapeutics, Inc. discovers and develops medicines for cancer and other genetically driven diseases. Its drug discovery engine deploys screening and structure-based approaches across broad families of targets involved in tumor metabolism, epigenetics, protein homeostasis, and protein-protein interactions. The company was founded by Steven Tregay, Nikolai Kley, Stuart L. Schreiber, Todd R. Golub, Michael Foley and Alexis Borisy in 2008 and is headquartered in Watertown, MA. | 1 Jahre |
| Peter Kornicker | M | - | 20 Jahre | |
| Dimitri Azar | M | 65 | 7 Jahre | |
| Tonya Williams | F | 50 | 1 Jahre | |
| Kim Stratton | F | 62 | 3 Jahre | |
| Michael Dybbs | M | 49 | 2 Jahre | |
| David Perry | M | 56 | 6 Jahre | |
| Shannon Klinger | M | 53 | 10 Jahre | |
| Michael Rogers | M | 64 | 4 Jahre | |
| Georges Gemayel | M | 64 | 2 Jahre | |
| Alan Colowick | M | 61 | 2 Jahre | |
| Tai Ching Ho | M | 62 | 3 Jahre | |
| Mun Tak Yang | F | 70 | - | |
| Ann Marie Fudge | F | 72 | - | |
| William Brody | M | 80 | - | |
| Alexandre F. Jetzer-Chung | M | 83 | 15 Jahre | |
| Chidozie Ugwumba | M | 41 | 4 Jahre | |
| Yi Li Xie | M | 54 | 2 Jahre | |
| Srikant T. Madhav Datar | M | 70 | 18 Jahre | |
| Jürgen Brokatzky-Geiger | M | 72 | 14 Jahre | |
| Andreas von Planta | M | 68 | - | |
| Amato Giaccia | M | 65 | 6 Jahre | |
| Sigurd Kirk | M | 57 | 3 Jahre | |
| George Migausky | M | 69 | 2 Jahre | |
| Gary Sutton | M | - | 13 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 72 | 72,00% |
| Schweiz | 28 | 28,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- John Hohneker
- Persönliches Netzwerk
